Intellia Therapeutics Reveals Publication Of Interim Phase 1 Data For NTLA-2002 In Patients With Hereditary Angioedema In The New England Journal Of Medicine
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics announced the publication of interim Phase 1 data for NTLA-2002 in the New England Journal of Medicine, showing its potential to eliminate angioedema attacks in patients with hereditary angioedema (HAE) after a single dose. The data also indicated that NTLA-2002 was well-tolerated across all dose levels.
January 31, 2024 | 10:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intellia Therapeutics' NTLA-2002 interim Phase 1 data suggests it could eliminate HAE attacks with one dose and has good tolerability, potentially boosting the company's prospects.
The positive interim Phase 1 data for NTLA-2002 published in a reputable medical journal suggests a high potential for the drug's success, which could lead to increased investor confidence and a positive impact on Intellia Therapeutics' stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100